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Viral variants of different phenotypes are present in the central nervous system (CNS) and lymphoid tissues
of carrier mice infected at birth with the Armstrong strain of lymphocytic choriomeningitis virus. The CNS
isolates are similar to the parental virus and cause acute infections in adult mice, whereas the lymphoid isolates
cause chronic infections associated with suppressed T-cell responses. In this study, we provide a molecular basis
for this organ-specific selection and identify a single amino acid change in the viral glycoprotein that correlates
with the tissue specific selection and the persistent and immunosuppressive phenotype of the variants. This
phenylalanine (F)-to-leucine (L) change at position 260 of the viral glycoprotein was seen in the vast majority
(43 of 47) of the lymphoid isolates, and variants with L at this residue were selected in spleens of persistently
infected mice. In striking contrast, isolates with the parental sequence (F at residue 260) predominated (48 of
59 isolates) in the CNS of the same carrier mice. Complete nucleotide sequence analysis of the major structural
genes of several independently derived (from different mice) spleen isolates showed that these variants were
>99.8% identical to the parental virus. In fact, the only common change among these spleen isolates was the
F-*L mutation at residue 260 of the glycoprotein. These results show that an RNA virus can exhibit minimal
genetic drift during chronic infection in its natural host, and yet a single or few mutations can result in the
organ-specific selection of variants that are markedly different from the parental virus.
The genetic changes and selective pressures involved in
the emergence of viral variants in vivo are not well under-
stood. To address this fundamental issue, we have been
studying the evolution of lymphocytic choriomeningitis virus
(LCMV) in its natural host (2, 13). Our previous studies have
documented the importance of host tissues in the selection of
viral variants during chronic LCMV infection. We have
shown that LCMV isolates of different phenotypes predom-
inate in the central nervous system (CNS) and lymphoid
tissue of carrier mice infected at birth with the Armstrong
strain of LCMV. Most of the CNS isolates are similar to the
parental Armstrong strain and induce potent virus-specific
cytotoxic T-lymphocyte (CTL) and delayed-type hypersen-
sitivity responses in adult mice, and the infection is cleared
within 2 weeks. In contrast, LCMV clones derived from the
lymphoid tissue of carrier mice cause persistent infections in
adult mice associated with suppressed T-cell responses and
susceptibility to opportunistic infections (3, 4, 26). To deter-
mine the genetic basis of the organ-specific selection and to
understand the mechanism of viral persistence and immune
suppression, we have conducted a molecular analysis of
these naturally selected LCMV variants.
The LCMV genome consists of two segments of single-
stranded RNA: a large (L) segment of 7.2 kb and a small (S)
segment of 3.4 kb (4, 18, 20, 22, 23). The L RNA segment
codes for a large protein, L (molecular size, 250 kDa), that is
believed to be the viral polymerase, and also contains a
second open reading frame, designated Z, that encodes for a
protein of approximately 10 to 12 kDa. The S segment codes
for the three major structural proteins: the internal nucleo-
capsid (63 kDa) and the two surface glycoproteins GP-1 (43
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kDa) and GP-2 (36 kDa) that are derived from a common
precursor polypeptide, GP-C.
In this study, we identify a single amino acid change in the
viral glycoprotein that correlates with the organ-specific
selection and the persistent and immunosuppressive pheno-
type of the variants. This phenylalanine (F)-*leucine (L)
change is seen in >95% of the lymphoid isolates, and
mutants with L at residue 260 of the viral glycoprotein are
selected in the spleens of carrier mice, whereas LCMV
isolates with the parental genotype (F at residue 260) pre-
dominate in the CNS.
MATERIALS AND METHODS
Mice. BALB/cByJ mice were purchased from Jackson
Laboratory, Bar Harbor, Maine. Neonatally infected carri-
ers were made by injecting 104 PFU of LCMV intracere-
brally into mice within 24 h of birth. The congenital carrier
colony was derived from these neonatally infected mice and
bred at the University of California at Los Angeles.
Virus. The Armstrong CA 1371 strain of LCMV was used
in these studies (3). The virus was triple plaque purified on
Vero cells, and stocks were grown in BHK-21 cells. This
original laboratory stock ofCA 1371 will be referred to as the
parental Armstrong strain. The carrier colony was originally
started by infecting 1-day-old mice with this strain. The CNS
and lymphoid isolates obtained from LCMV carrier mice
were also plaque purified three times. Virus stocks (grown in
BHK cells) at passage 1 or passage 2 levels were used in
subsequent experiments. The biological properties of the
various isolates are extremely stable in tissue culture, and
we have had no reversion of the phenotype during the plaque
purification on Vero cells or growth in BHK cells.
Virus titration. Infectious LCMV was quantitated by
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plaque assay on Vero cell monolayers as previously de-
scribed (3).
Generation of reassortants. Coinfection of BHK-21 cells
and the procedures used to screen the progeny for reassor-
tants were as previously described (4).
CTL assay. LCMV-specific CTL activities in spleens and
lymph nodes were determined by a 6-h 51Cr release assay as
previously described (3).
Sequence analysis. The L and S segments of the parental
Armstrong strain and the spleen variants were sequenced by
the primer extension method, using virus-specific oligonu-
cleotides (11, 14, 19). Either 1 to 3 ,ug of viral RNA extracted
from purified virus or 50 ,ug of total infected cell RNA was
used for the sequencing reactions.
Oligonucleotide hybridization. Matching sets of oligonucle-
otides specific either for the parental Armstrong sequence or
the spleen variant clone 13 sequence were used to determine
the viral RNA sequence of the CNS and lymphoid isolates at
nucleotide residues 855 and 1298. The pairs of oligonucleo-
tides used were as follows: for nucleotide residue 855,
Armstrong-specific 5'-GTCTCCTAGTGAAGAACTTA-3'
and clone 13-specific 5'-GTCTCCTAGTGAGGAACTTA-3',
and for residue 1298, Armstrong-specific 5'-TTCGATTTGA
TCACTGAAGT-3' and clone 13-specific 5'-TTCGATTTGG
TCACTGAAGT-3'. Total RNA was extracted from infected
BHK-21 cells by the guanidinium thiocyanate-CsCl proce-
dure (8). The RNA samples were denatured with formalde-
hyde, and 5 ,ug ofRNA was dotted onto nitrocellulose paper
with a 96-hole Bio-Dot apparatus. Duplicate filters of each
viral RNA sample were hybridized with 32P-labeled oligonu-
cleotides that were specific either for the parental Armstrong
sequence or for the spleen variant clone 13 sequence. The
pairs of oligonucleotides used differ at only one residue, and
washing conditions were used such that a single mismatch
resulted in complete loss of hybridization. To determine the
amount of viral RNA in each sample, an additional filter was
hybridized with a 32P-labeled cDNA probe that hybridizes
equally well with the S RNA segment of both parental
Armstrong virus and the spleen variant clone 13 (4, 23).
RESULTS
Genetic analysis of one spleen isolate, clone 13, has shown
that biologically important mutations occurred in both the L
and S RNA segments (4, 14). Replacing the L or S segment
of clone 13 with the parental Armstrong L or S segment
profoundly affected its ability to persist and cause immune
suppression in adult mice (Table 1). The precise changes in
the L segment of clone 13 have not yet been identified, but
complete sequence analysis of the S segment of clone 13 has
revealed two differences (at nucleotide positions 855 and
1298) in the glycoprotein gene compared with the parental
Armstrong virus (14, 19). Both of these were U->C changes;
the one at position 855 resulted in an F->L change at amino
acid residue 260, whereas the one at position 1298 was silent
(Fig. 1). There were no mutations in the nucleoprotein gene,
the intergenic region, or the noncoding regions at the 5' and
3' ends of the S segment.
It was of interest to determine whether mutations seen in
the glycoprotein gene of this one particular spleen isolate
would be found in other lymphoid isolates, and more impor-
tantly to ascertain whether these genetic changes were
involved in the organ-specific selection of LCMV variants.
To address this question, the sequences of several indepen-
dently derived spleen and brain isolates obtained from
BALB/c carrier mice infected at birth with the Armstrong
TABLE 1. Genetic evidence showing that mutations in the S and
L segments of spleen isolate clone 13 affect ability to persist
in adult mice
% Specific 5"Cr release from
BALB Cl7 (H-2d) targetsb
Virus and genotypea LCMV infected Unin- LCMV titer in se-
_____________fected, rum (logl0 PFU/ml)c
5.5:1 16.6:1 50:1 50:1 8 15 30
Parental Armstrong, 33 59 82 6 <1.6 <1.6 <1.6
A/A
Spleen variant clone 0 3 11 1 5.9 5.7 4.4
13, svAlsvA
Reassortant C406al, 13 45 61 1 3.5 <1.6 <1.6
svAIA
Reassortant T800, 20 41 59 3 3.3 <1.6 <1.6
AIsvA
a Adult BALB/c mice were infected intravenously with 106 PFU of the
indicated virus. The following notation is used to indicate genotype: A/A,
virus with both L and S segments of parental Armstrong; svA/svA, virus with
both L and S segments of spleen variant clone 13; svA/A, reassortant with L
segment of spleen variant clone 13 and S segment of parental Armstrong;
A/svA, reassortant with L segment of parental Armstrong and S segment of
Clone 13.
b CTL response was checked 8 days postinfection at the indicated E/T
ratios. Data are averages for three mice per group.
c Mice were eye-bled on the indicated days postinfection, and the titer of
infectious LCMV in the serum was determined by a plaque assay on Vero
cells. Data are averages for three to six mice per group.
strain were determined. Sequences at the two sites showing
changes (positions 855 and 1298) were analyzed by oligonu-
cleotide hybridization (see Materials and Methods). This
technique allows rapid screening of a large number of viral
isolates. Using this method, we analyzed >100 LCMV brain
and spleen isolates. Many of these isolates were indepen-
dently derived (i.e., isolated from different carrier mice).
The silent U--C change at nucleotide position 1298 was not
seen in any of the brain or spleen isolates, indicating that this
was a random mutation in clone 13 and unlikely to be of any
biological significance (data not shown). In contrast, the
mutation at nucleotide position 855 (amino acid residue 260)
It
3'5,
GP-C
Position of Change Parental
*855
#1298
NP
Variant
UUC - CUC
(F) (L)
GAU - '> GAC
(D) (D)
FIG. 1. Sequence differences between the S segments of parental
Armstrong and spleen variant clone 13. The S segments (3,376
bases) of these two viruses show only two nucleotide changes, both
in the glycoprotein gene. The mutation at position 855 results in an
F- L change, whereas the mutation at position 1298 is silent. There
are no nucleotide changes in the nucleoprotein gene, the intergenic
region, or the noncoding regions at the 5' and 3' ends of the S
segment.
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LCMV Spleen Isolates
Probe
S
A 13 C Ila 12a 13a 14a 16a
* 0 *
20-mer (A)
20-mer (13) * * * * *
LCMV Brain Isolates
Probe
S
2b 5a 6a 70 9a 17a 20a
:.:
..* .* 9 *
20-mer(A) 0 * 0 0
20-mer (13) 0 *
FIG. 2. Identification of nucleotide residue 855 of the viral glyco-
protein gene by hybridization with oligonucleotides specific for the
parental Armstrong or spleen variant clone 13 sequence. Total RNA
was extracted from infected BHK-21 cells by the guanidinium thio-
cyanate-CsCl procedure. The RNA samples were denatured with
formaldehyde, and 5 ,ug ofRNA was dotted onto nitrocellulose paper
in a 96-hole Bio-Dot apparatus. Triplicate filters of each sample were
made and hybridized with a 32P-labeled cDNA probe (S) that hybrid-
izes with the small RNA segment of both Armstrong and clone 13
RNA and with 32P-labeled oligonucleotides (20-mers) that specifically
hybridize with either the parental Armstrong (A) or clone 13 (13)
RNA, respectively. The two oligonucleotides used (clone 13 specific,
5'-GTCTCCTAGTGAQGAACTTA-3'; Armstrong specific, 5'-GT
CTCCTAGTGAAGAACTTA-3') differ at only one residue, and
washing conditions were used such that a single mismatch resulted
in complete loss of hybridization. Sample C designates RNA from
uninfected BHK cells. Samples lla, 12a, 13a, 14a, and 16a are
independently derived (from different mice) spleen isolates from five
2-month-old LCMV carrier mice; samples 2b, 5a, 6a, 7a, 9a, 17a,
and 20a are brain isolates obtained from the same five carrier mice.
was found in the vast majority of the lymphoid isolates (Fig.
2 and Table 2). Of the 47 spleen isolates tested, 43 (>90%)
had L at residue 260 of the glycoprotein gene and only 4
isolates had the parental Armstrong sequence (F at residue
TABLE 2. Organ-specific selection of LCMV variants with
leucine at residue 260 of viral glycoprotein during
chronic infectiona
Origin of LCMV Total no. No. with phenylalanine No. with leucine
isolates analyzed at residue 260 of at residue 260 ofglycoprotein glycoprotein
Parental Armstrong 20 20 0
Carrier brain 59 48 11
Carrier spleen 47 4 43
a LCMV isolates were obtained from the brains and spleens of BALB/c
carrier mice infected at birth with the parental Armstrong strain. The viruses
analyzed were isolated from 1- to five-month-old LCMV carrier mice. Fifteen
carrier mice were used in this analysis, and therefore many of the LCMV
isolates were truly independently derived (i.e., isolated from different carrier
mice). The CNS and lymphoid isolates of LCMV were plaque purified three
times on Vero cells, and then stocks were grown in BHK-21 cells. The
sequence at amino acid residue 260 of viral glycoprotein was determined by
the oligonucleotide hybridization technique shown in Fig. 2 and further
confirmed for some isolates by direct sequencing of the viral RNA by the
primer extension method.
260). The presence of this F-*L mutation in the spleen
isolates was further confirmed for several of these isolates by
directly sequencing the viral RNA in this region by the
primer extension method. Strikingly, the brain isolates
showed the reverse pattern; the majority (48 of 59, or 81%)
of the isolates still retained the original Armstrong glycopro-
tein sequence (Fig. 2 and Table 2). The data in Table 2 also
show that the parental Armstrong strain that was used to
initiate the chronic infection was reasonably homogeneous
and that all 20 clones analyzed had F at residue 260 of the
viral glycoprotein. These results clearly document the im-
portance of this F- L mutation in the organ-specific selec-
tion of viral variants during persistent LCMV infection.
We next determined whether acquisition of this F-*L
change in the viral glycoprotein correlated with the ability to
persist in adult mice and suppress T-cell responses. As
shown in Fig. 3, the vast majority (24 of 29) of LCMV
isolates with L at residue 260 were present at high levels
(>104 PFU per spleen) in the spleens of adult mice at 8 days
postinfection, and these mice contained low levels of
LCMV-specific CTL. In contrast, most (15 of 17) of the
isolates with F were similar to the parental Armstrong strain,
and adult mice infected with these isolates contained low
levels of virus (<102 PFU per spleen) and exhibited a potent
LCMV-specific CTL response. By day 15 postinfection, all
17 isolates containing F had been eliminated from adult
mice, whereas 24 of 29 variants with L were present at high
levels (>10W PFU) in the serum and spleen (data not shown).
These mice continued to harbor virus for several months.
These results clearly establish a strong correlation between
the F-*L amino acid change in the glycoprotein and the
persistent and immunosuppressive phenotype of the spleen
isolates. Figure 3 also shows the strong correlation that
exists between LCMV-specific CTL response and viral
clearance.
The data presented in Fig. 3 provide strong evidence
linking the F-sL change with persistence in adult mice.
However, the correlation was not absolute, and five of the 29
isolates (-17%) tested had not acquired the persistent phe-
notype despite having the F-tL mutation. These results are
not totally unexpected since we have shown (Table 1) that
the complete spleen variant phenotype is due to mutations in
both the S and L viral RNA segments (4, 14). Thus, it is
likely that the five isolates shown in Fig. 3 represent an
intermediate stage in their transition from the parental virus
to the spleen isolate phenotype; these isolates have acquired
the F-sL change in the viral glycoprotein, but the critical
mutation(s) in the L segment is yet to occur. A prediction
based on the results shown in Table 1 and Fig. 3 is that all
F-sL variants derived from a reassortant (svA/A) that con-
tains the L segment of spleen variant clone 13 and the S
segment of parental Armstrong should behave exactly like
clone 13. In other words, isolates derived from carrier mice
infected with the reassortant svA/A should show a perfect
correlation between the F-sL mutation and the persistent
and immunosuppressive phenotype, since the biologically
relevant change in the L segment is already present in the
parental virus. This was tested by obtaining isolates from
BALB/c mice infected at birth with the reassortant svA/A.
As shown in Table 3, there was a complete correlation
between the F--L mutation and acquisition of the persistent
and immunosuppressive phenotype.
To determine the extent of genetic drift in variants isolated
from carrier mice, we sequenced the complete S segment of
several independently derived spleen isolates (i.e., isolated
from different carrier mice). As summarized in Table 4, these
J. VIROL.
ORGAN-SPECIFIC SELECTION OF VIRAL VARIANTS 4245
spleen isolates (F) -
spleen isolates (L) C
brain isolates (F) 0
brain isolates (L) 0
parental virus (F) A
E0
00
0- w-
4
LCMV titer
Log10 PFU/spleen
oO
5
w
6
FIG. 3. Correlation between F- L mutation in the glycoprotein and the ability of LCMV variants to persist in adult mice. Two-month-old
BALB/c mice were infected intravenously with 106 PFU of the indicated LCMV brain or spleen isolate containing either F or L at residue
260 of viral glycoprotein. The CTL activity in the spleens of mice infected with a particular viral isolate is plotted against the titer of infectious
LCMV in the spleens of the same group of mice. Data are averages for three to four mice per group. Virus titer and LCMV-specific CTL
activity in spleen were checked eight days after infection, which is the peak of the primary CTL response.
spleen isolates exhibited a surprisingly high level of conser-
vation and showed >99.8% overall identity at the nucleotide
level with the S segment of the parental Armstrong virus. In
fact, the only common change among these five spleen
isolates was the F-*L mutation at residue 260 of the viral
glycoprotein. Sequence analysis of the L segments of these
variants also indicated a similar level of conservation; no
mutations have been detected in the 2,500 nucleotides of the
TABLE 3. Biological characterization of spleen isolates derived
from reassortant svA/Aa
% Specific 5"Cr re- LCMV titer
Amino acid lease from BALB in serum
at residue C17 (H-2d) targets (logl0 PFU/
Virus 260 of gly- (E/T, 50:1) ml)
coprotein LCMV Unin- 8b 15
infected fected
Parental svA/A F 57 0 3.5 <1.6
Spleen isolate
24 L 7 1 5.2 5.3
26 L 2 0 5.7 5.5
28 L 6 0 5.7 5.4
33 L 4 0 5.9 5.6
36 L 9 0 5.7 5.6
32 F 59 1 3.6 <1.6
a Adult BALB/c mice were infected intravenously with 106 PFU of the
indicated virus. CTL response and virus titer were checked 8 days after
infection. Data are averages for two to four mice per group. The spleen
isolates used in this study were obtained from 15-day-old BALB/c mice
infected at birth with the reassortant svA/A.
b Days postinfection.
polymerase gene that have been sequenced so far (data not
shown). These results show that LCMV undergoes minimal
genetic drift during chronic infection in vivo and that a single
or few mutations can result in the organ-specific selection
and emergence of variants with profoundly altered biological
properties.
TABLE 4. Minimal genetic drift in LCMV variants selected in
spleens of carrier mice
b % Identity with paren-
Spleen No. of nucleotide changes tal Armstrong virus
isolate' Nucleoprotein Glycoprotein gene Nucleotide Amino acid
gene (1,677 bases) (1,497 bases) level level
M10.lA 1 (1) 4 (2) 99.84 99.71
M2.1A 1 (1) 5 (3) 99.81 99.62
T5.1OA 1 (1) 4 (3) 99.84 99.62
tlb 1 (1) 3 (3) 99.87 99.62
Clone 13 0 2 (1) 99.93 99.90
a Obtained from three BALB/c carrier mice. Clone 13 was isolated from the
spleen of a 2-month-old carrier mouse infected at birth with the parental
Armstrong virus, isolate M10.lA was obtained from a 3-month-old congeni-
tally infected carrier mouse (third generation), and isolates M2.1A, T5.10A,
and tlb were obtained from spleens of different congenitally infected carriers.
The congenital carrier colony was originally started by infecting 1-day-old
BALB/c mice with Armstrong virus. All spleen isolates were triple plaque
purified prior to use.
b Sequencing of the spleen isolates and Armstrong virus was done by the
primer extension method using specific oligonucleotides. Numbers in paren-
theses represent number of amino acid changes.
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DISCUSSION
This study provides a molecular basis for the organ-
specific selection of LCMV variants during chronic infec-
tion. Our results identify a single amino acid change in the
viral glycoprotein that is found in viral isolates obtained from
lymphoid tissue but is absent in viral isolates derived from
CNS of the same mice. This F->L change is seen in >95% of
the lymphoid isolates, and mutants with L at position 260 of
the viral glycoprotein are selected in spleens of persistently
infected mice, whereas LCMV isolates with the parental
sequence (F at residue 260) predominate in the CNS.
It is of particular interest that the lymphoid isolates exhibit
minimal genetic drift. Complete sequence analysis of the
major structural genes of several independently derived
spleen isolates shows that these variants are >99.8% iden-
tical to the parental virus. In fact, the only common change
among these spleen isolates is the F--L mutation at residue
260 of the glycoprotein. These results show that, contrary to
dogma, chronic infection with an RNA virus does not
necessarily result in extensive genetic variation (12, 24).
However, one or few mutations are sufficient to result in the
organ-specific selection of variants that show major biolog-
ical differences compared with the parental virus. These
results emphasize the importance of selection and the role of
host tissues in the emergence of viral variants in vivo.
The significance of this F-*L change was confirmed by
making reassortants between a spleen isolate, clone 13, and
the parental Armstrong virus. Reassortant svA/A (L seg-
ment of clone 13 and S segment of parental Armstrong) is
unable to persist in adult mice and is eliminated within 2 to
3 weeks. In contrast, clone 13 (svA/svA), which differs from
svA/A by only this single F--L change in the glycoprotein,
persists in adult mice for several months. It is worth noting
that in an earlier study in which reassortants between clone
13 and the Pasteur strain of LCMV were tested, the reassor-
tant svA/P (L segment of clone 13 and S segment of the
Pasteur strain) was almost as persistent as clone 13 in adult
mice. In retrospect, this result is not surprising since the
Pasteur strain, similar to the spleen variants of Armstrong,
has L at residue 260 of the glycoprotein (19). Thus, the
different phenotypes of svA/A and svA/P are most likely due
to the sequence difference at position 260 of the glycoprotein
(L for Pasteur and F for Armstrong).
The spleen isolates and the parental Armstrong virus grow
equally well in mouse fibroblasts, but the spleen isolates
show enhanced replication in macrophages and lymphocytes
(13). This selective growth advantage in cells of the immune
system explains the emergence of these variants in spleens
of carrier mice. In contrast to the selection of variants
containing the F->L mutation in the spleen, the parental
genotype predominates in the CNS. Previous studies have
shown that although a variety of cell types in the CNS can be
infected by LCMV, infection is confined predominantly to
neurons in neonatally infected carrier mice (10, 17). Thus,
growth potential in neurons is likely to be an important
determinant in the selection of viral variants in the CNS.
Experiments are currently in progress to compare the ability
of the various isolates to replicate in neurons in vitro as well
as in vivo. The results presented in this report strongly
suggest that the parental virus grows at least as well as, if not
better than, the variants (with the F->L mutation) in the
CNS. In this context, it is worth noting that the parental
Armstrong virus was originally maintained by brain-ibrain
passage in mice before a clone was obtained by plaque
purification (9). Thus, the parental Armstrong virus most
likely represents a brain-adapted strain of LCMV.
The F at residue 260 of the parental Armstrong virus is
encoded by a UUC codon. This can change to a codon
specifying L by three different single-base substitutions;
UUC->CUC, UUC-*UU£, or UUC-*UUA. In the LCMV
variants that we analyzed, this F->L change always oc-
curred by a U-*C mutation. This is somewhat surprising, but
it should be noted that of the three possibilities, two are
transversions (C->G and C--A) whereas the U- C change is
a transition. Since transitions occur more readily than trans-
versions, this may explain our findings (25). Also, studies on
genetic variation in measles virus during chronic infection in
vivo have shown a high frequency of U->C mutations in the
measles genome (7).
How does the F-*L mutation in the glycoprotein have
such a profound effect on the selection of variants in
lymphoid tissue? It is worth noting that the F--L mutation is
close to the putative cleavage site of the viral glycoprotein
(6). Proper proteolytic cleavage is essential for infectivity,
and alterations in the processing or stability of the viral
glycoprotein are likely to affect the growth rate of the virus.
It is currently not known whether cleavage of the LCMV
glycoprotein is mediated by a viral or cellular protease(s). If
a cellular protease(s) is involved, it might be possible to
explain our findings on the basis of different proteases being
present in different cell types (for example, macrophages
versus neurons). Clearly, additional experiments are needed
to resolve this issue. Nevertheless, it is clear from our
studies that this single amino acid change determines the
selection of variants in an organ-specific manner.
The F->L mutation also correlates with the persistent and
immunosuppressive phenotype of the LCMV variants. The
enhanced growth capability of these variants in lymphocytes
and macrophages is a likely explanation for the ability of the
spleen variants to establish chronic infections in adult mice
(13). The observed immune suppression may also be due to
increased growth in lymphoid tissue and greater dissemina-
tion of the virus. The F-*L change in the glycoprotein is not
within any of the CTL epitopes, and therefore it is unlikely
that the low level of LCMV-specific CTL response detect-
able in mice infected with the spleen isolates is due to altered
recognition of T-cell epitopes (16, 21). In fact, the spleen
isolates are recognized both in vitro and in vivo by LCMV-
specific CTL induced by the parental Armstrong virus.
H-2-matched targets infected by the variants are efficiently
killed by LCMV-specific CTL in vitro, and transfer of these
CTL into mice infected with the variants results in rapid
elimination of virus in vivo (1, 4).
It will be of interest to identify the mutations in the L
segment that affect viral persistence and the tissue specific
selection. About 2,500 nucleotides of the polymerase gene of
several spleen isolates have been sequenced so far, and no
changes have been detected. This result further attests to the
extreme conservation of the LCMV genome during chronic
infection.
In conclusion, this study shows that a virus can exhibit
minimal genetic drift during chronic infection in its natural
host and yet a single or few mutations can result in the
organ-specific selection of variants that are markedly dif-
ferent from the parental virus. These results document the
role of host tissues in virus evolution and emphasize the
importance of selection in the emergence of viral variants in
vivo. These observations suggest a possible mechanism by
which viral variants emerge in nature and provide a frame-
J. VIROL.
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work for understanding the evolution of other viruses, in
particular viruses that cause chronic infections (15).
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